DE69422742T2 - Phenoxyphenylessigsäurederivate - Google Patents

Phenoxyphenylessigsäurederivate

Info

Publication number
DE69422742T2
DE69422742T2 DE69422742T DE69422742T DE69422742T2 DE 69422742 T2 DE69422742 T2 DE 69422742T2 DE 69422742 T DE69422742 T DE 69422742T DE 69422742 T DE69422742 T DE 69422742T DE 69422742 T2 DE69422742 T2 DE 69422742T2
Authority
DE
Germany
Prior art keywords
acid derivatives
phenoxyphenylacetic acid
phenoxyphenylacetic
derivatives
vasospasm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69422742T
Other languages
English (en)
Other versions
DE69422742D1 (de
Inventor
William J Greenlee
Thomas F Walsh
Douglas J Pettibone
James R Tata
Ralph A Rivero
David L Williams
Scott W Bagley
Daljit S Dhanoa
Prasun K Chakravarty
Kenneth J Fitch
Theodore P Broten
Nancy Jo Kevin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE69422742D1 publication Critical patent/DE69422742D1/de
Publication of DE69422742T2 publication Critical patent/DE69422742T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE69422742T 1993-03-19 1994-03-10 Phenoxyphenylessigsäurederivate Expired - Fee Related DE69422742T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3445593A 1993-03-19 1993-03-19
US19746794A 1994-02-24 1994-02-24

Publications (2)

Publication Number Publication Date
DE69422742D1 DE69422742D1 (de) 2000-03-02
DE69422742T2 true DE69422742T2 (de) 2000-08-17

Family

ID=26710968

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69422742T Expired - Fee Related DE69422742T2 (de) 1993-03-19 1994-03-10 Phenoxyphenylessigsäurederivate

Country Status (23)

Country Link
EP (1) EP0617001B1 (de)
JP (1) JPH08508034A (de)
KR (1) KR960700992A (de)
CN (1) CN1119434A (de)
AT (1) ATE189217T1 (de)
AU (1) AU679710B2 (de)
CA (1) CA2119051A1 (de)
CZ (1) CZ233595A3 (de)
DE (1) DE69422742T2 (de)
DK (1) DK0617001T3 (de)
ES (1) ES2141197T3 (de)
FI (1) FI954404A0 (de)
GR (1) GR3032643T3 (de)
HR (1) HRP940179B1 (de)
HU (1) HU217028B (de)
IL (1) IL108944A0 (de)
NO (1) NO953672L (de)
NZ (1) NZ263414A (de)
PL (1) PL175786B1 (de)
PT (1) PT617001E (de)
RU (1) RU2139273C1 (de)
SK (1) SK114795A3 (de)
WO (1) WO1994021590A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124343A (en) * 1919-01-27 2000-09-26 Rhone-Poulenc Rorer Limited Substituted phenyl compounds with a substituent having a thienyl ring
WO1996022978A1 (en) * 1995-01-27 1996-08-01 Rhone Poulenc Rorer Limited Substituted phenyl compounds as endothelin antagonists
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
JPH10503779A (ja) * 1994-08-08 1998-04-07 メルク エンド カンパニー インコーポレーテッド フェノキシフェニル酢酸誘導体
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
DE19527568A1 (de) 1995-07-28 1997-01-30 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
DE19528418A1 (de) * 1995-08-02 1997-02-06 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19530032A1 (de) * 1995-08-16 1997-02-20 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19537548A1 (de) * 1995-10-09 1997-04-10 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
EP0873334A1 (de) * 1995-12-12 1998-10-28 Merck & Co., Inc. (a New Jersey corp.) Verfahren zur herstellung von endothelin antagonist
US5688974A (en) * 1995-12-12 1997-11-18 Merck & Co., Inc. Process for the preparation of an endothelin antagonist
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US6090836A (en) * 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states
CA2244831A1 (en) * 1996-02-02 1997-08-07 John T. Olson Method of treating diabetes and related disease states
BR9708151A (pt) 1996-02-20 1999-07-27 Bristol Myers Squibb Co Processo para a preparaç o de bifenil isoxazol sulfonamidas
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
GB9609641D0 (en) 1996-05-09 1996-07-10 Pfizer Ltd Compounds useful in therapy
DE19653024A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DE19710831A1 (de) * 1997-03-15 1998-09-17 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
HU226454B1 (en) * 1997-09-26 2008-12-29 Abbott Gmbh & Co Kg Endothelin antagonist pyrimidin derivatives and renin-angiotensin system inhibitors as synergistic combined preparations and process for producing them
DE19743143A1 (de) * 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
GB9722287D0 (en) * 1997-10-22 1997-12-17 Pfizer Ltd Compounds useful in therapy
DE19747788A1 (de) 1997-10-29 1999-05-06 Basf Ag Substituierte 2-(2'-Pyridyloxy)phenylessigsäureamide, ihre Herstellung und Verwendung, sowie sie enthaltende Mittel
WO1999048530A1 (en) * 1998-03-23 1999-09-30 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
AU746043B2 (en) 1998-03-31 2002-04-11 Tanabe Seiyaku Co., Ltd. Preventives/remedies for urinary disorder
US6017918A (en) * 1998-08-06 2000-01-25 Warner-Lambert Company Phenyl glycine compounds and methods of treating atherosclerosis and restenosis
US6284795B1 (en) 1998-09-04 2001-09-04 Warner-Lambert Company Sulfonamide compounds and methods of treating atherosclerosis and restenosis
MXPA01009362A (es) 1999-03-19 2002-06-04 Squibb Bristol Myers Co Metodos para la preparacion de bifenil isoxazol sulfonamidas.
WO2001027077A2 (en) * 1999-10-12 2001-04-19 Basf Aktiengesellschaft Hydroxysulfonylalkylene-, phosphonoalkylene- or difluoro(phosphononon)methyl- substituted benzene, or benzofuran derivatives as non-peptidic cdc25 inhibitors
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
AU2002251978B2 (en) * 2001-02-09 2007-07-19 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
CN100338073C (zh) * 2002-03-20 2007-09-19 麦它波莱克斯股份有限公司 取代的苯乙酸
US8614236B2 (en) 2006-12-12 2013-12-24 University Of Washington Methods of treating pulmonary disease using acetazolamide and structurally related derivatives
CN101042381B (zh) * 2007-04-28 2014-01-08 长春迈灵生物工程有限公司 一种地舍平的检测方法
KR20120130078A (ko) * 2009-11-09 2012-11-28 메디비르 아베 신규한 1,3-옥사졸리딘 화합물 및 이의 레닌 억제제로서의 용도
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
EP2593433B1 (de) 2010-07-12 2014-11-26 Pfizer Limited N-sulfonylbenzamide als inhibitoren von spannungsabhängigen natriumkanälen
EP2593432B1 (de) 2010-07-12 2014-10-22 Pfizer Limited N-sulfonylbenzamidderivate als spannungsgesteuerte natriumkanalhemmer
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
ES2532357T3 (es) 2010-07-12 2015-03-26 Pfizer Limited Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
BR112013016033A2 (pt) 2010-12-23 2018-06-05 Pfizer moduladores do receptor de glucagon
EA023517B1 (ru) 2011-02-08 2016-06-30 Пфайзер Инк. Модуляторы глюкагонового рецептора
BR112014000288A2 (pt) 2011-07-22 2017-01-10 Pfizer moduladores do receptor de glucagon de quinolinila
CA2857603C (en) 2011-12-15 2016-08-02 Pfizer Limited Sulfonamide derivatives
CN111825564B (zh) * 2020-09-21 2020-12-29 西藏甘露藏药股份有限公司 一种从渣驯中提取的化合物、制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1408738A (fr) * 1964-04-29 1965-08-20 Nobel Bozel Nouveaux dérivés de l'acide bis(hydroxy-4-phényl)-acétique
US4748272A (en) * 1986-08-01 1988-05-31 Rorer Pharmaceutical Corp. Phenoxyphenylacetates for use as potential modulators of arichidonic acid pathways
JPS63122605A (ja) * 1986-11-10 1988-05-26 Tokuyama Soda Co Ltd 除草剤組成物

Also Published As

Publication number Publication date
NO953672D0 (no) 1995-09-18
SK114795A3 (en) 1996-06-05
EP0617001A1 (de) 1994-09-28
CN1119434A (zh) 1996-03-27
IL108944A0 (en) 1994-06-24
ATE189217T1 (de) 2000-02-15
HU217028B (hu) 1999-11-29
KR960700992A (ko) 1996-02-24
HRP940179B1 (en) 2000-10-31
DK0617001T3 (da) 2000-04-17
PL175786B1 (pl) 1999-02-26
PL310661A1 (en) 1995-12-27
EP0617001B1 (de) 2000-01-26
DE69422742D1 (de) 2000-03-02
HUT73658A (en) 1996-09-30
ES2141197T3 (es) 2000-03-16
HRP940179A2 (en) 1998-02-28
RU2139273C1 (ru) 1999-10-10
WO1994021590A1 (en) 1994-09-29
FI954404A (fi) 1995-09-18
GR3032643T3 (en) 2000-06-30
CA2119051A1 (en) 1994-09-20
NO953672L (no) 1995-11-17
JPH08508034A (ja) 1996-08-27
CZ233595A3 (en) 1996-01-17
AU679710B2 (en) 1997-07-10
AU5787894A (en) 1994-09-22
FI954404A0 (fi) 1995-09-18
PT617001E (pt) 2000-06-30
HU9502725D0 (en) 1995-11-28
NZ263414A (en) 1997-09-22

Similar Documents

Publication Publication Date Title
ATE189217T1 (de) Phenoxyphenylessigsäurederivate
MX9308191A (es) Antagonistas de endotelina.
CY1105091T1 (el) Αντικατεστημενες ενωσεις 2-αρυλοβενζαζολιου και η χρηση τους σαν παραγοντες κατα των ογκων
AP9701004A0 (en) Low molecular weight bicyclic thrombin inhibitors.
TR200102612T2 (tr) Mide asidi salgılanmasını önleyen imidazo piridin türevleri.
NO20012966L (no) Kondenserte 1,2,4-tiadiazinderivater, deres fremstilling og anvendelse
HK1003031A1 (en) Condensed pyrimidine derivatives and their use as angiotensine ii antagonists
RU92004368A (ru) Замещенные пиримидины, способ их получения, фармацевтическая композиция
PT1023267E (pt) Compostos de piridilo e composicoes farmaceuticas que os contem
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
ATE292633T1 (de) Substituierte piperazinderivate und ihre verwendung als fettsaüreoxidationsinhibitoren
MX9202191A (es) Antagonistas de endotelina.
DE69528711D1 (de) Chinazolinen als inhibitoren des endothelin konvertierenden enzyme
PL326236A1 (en) Novel compounds - derivatives of sulphonylpyrimidine exhibiting anticarcinogenous effect and method of obtaining them
AR012094A1 (es) Derivados de quinolein-2(1h)-ona y de dihidroquinolein-2(1h)-ona, su preparacion y su aplicacion en terapeutica.
ATE86983T1 (de) Acyl-derivate von hydroxy-pyrimidinen.
ATE239721T1 (de) Zimtsäure-derivate als zelladhäsions-moleküle
MX12192A (es) Composicion farmaceutica para reducir o impedir las arritmias
WO2004052887A3 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
ES2157923T3 (es) Compuestos utiles para tratar enfermedades alergicas e inflamatorias.
MX9704594A (es) Peptidos heterociclicos de la ceto-arginina, como inhibidores de la trombina.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee